Not Losing Weight on Mounjaro 7.5mg? Here's What's Happening

You're on the third rung of a six-rung ladder

Picture the titration schedule as a set of steps. Mounjaro starts at 2.5mg, a tolerability dose, there to let your system settle rather than to drive meaningful weight change. Many people find progress at 5mg underwhelming for the same reason. At 7.5mg you're halfway up, and for a significant number of people the dose is still finding its ceiling effect.

Tirzepatide works by activating both GIP and GLP-1 receptors, slowing how quickly food leaves the stomach and dampening appetite signals. That dual mechanism is dose-dependent: the higher the dose, the stronger those effects. In the SURMOUNT-1 trial, participants on the 15mg dose lost around 20–21% of their body weight on average over 72 weeks. At lower doses the response was measurably smaller. That's not a failure of the medicine at 7.5mg, it's the expected pharmacology. Your prescriber is building toward the dose that works best for you, which for many people is 10mg or higher.

The NHS's guidance on tirzepatide confirms that treatment starts at 2.5mg and is titrated upward over time, the early doses are the preamble, not the main event.

Your body may have pressed pause on its own

A plateau at 7.5mg doesn't necessarily mean the medicine has stopped working. Metabolic adaptation is real: as you lose weight, your body adjusts its energy expenditure downward, making further loss harder even with the same calorie deficit. This happens on tirzepatide just as it does without it, though GLP-1 medicines tend to attenuate some of the appetite rebound that makes prolonged dieting so difficult unaided.

Sleep is one factor that surprises people. Poor sleep raises ghrelin (the hunger hormone) and lowers leptin, which can partially override the appetite suppression tirzepatide provides. If you're consistently getting fewer than six hours, that alone can stall the scales. Stress hormones have a similar effect on cortisol-driven hunger and water retention.

Gastrointestinal side effects at 7.5mg, covered in more detail in our side effects guide, can also lead people to unconsciously compensate by choosing softer, calorie-dense foods that go down more easily. A quick look at what you're actually eating during a nausea phase is worth doing before assuming the dose isn't working.

What you eat matters more than most people expect on a GLP-1

Mounjaro reduces appetite. It doesn't redirect appetite toward protein and vegetables. Some people find that when hunger drops, they eat less food overall but the food they do eat is more processed, crackers, yoghurts, small portions of whatever's easy to grab from the fridge at 6pm when cooking feels like too much effort.

Protein adequacy matters a great deal here. When you're in a calorie deficit, your body will lose muscle as well as fat unless protein intake is sufficient. Muscle tissue burns more energy at rest; losing it slows your metabolism further. Prescribers typically suggest prioritising protein at each small meal, even if total intake is modest. Fibre intake affects satiety and gut health, both of which interact with how GLP-1 medicines perform.

This isn't about calorie counting obsessively, it's about food quality within whatever appetite tirzepatide leaves you with. If you're unsure how your diet stacks up, a registered dietitian can help, and our prescribers can advise at your next review. You can also read more about how tirzepatide works and what to expect across the full treatment course.

Other medicines and health conditions can interfere

A handful of commonly prescribed medicines are associated with weight gain or blunted weight loss, regardless of treatment. These include certain antidepressants (notably mirtazapine and some SSRIs), antipsychotics, corticosteroids, insulin and some blood pressure medicines. If you've recently started or changed any of these, it's worth flagging to your prescriber alongside your tirzepatide review.

Hypothyroidism, polycystic ovary syndrome (PCOS) and insulin resistance all affect how readily the body mobilises fat. None rules out tirzepatide working well for you, but they may mean progress is slower and that higher doses are needed before you see the results the clinical trial population achieved on average.

The honest answer is that average trial results are averages. SURMOUNT-1 enrolled thousands of adults and the range of individual responses was wide. Some people lose steadily from the first dose change; others see most of their progress concentrate in the upper titration range. Neither pattern means the treatment is failing at 7.5mg. For context on how the full dose range compares, our 5mg overview explains what changes (and what doesn't) at each step. If you're weighing up the costs of continuing treatment, our Mounjaro pricing guide sets out what's changed in the UK market since 2025.

If you'd like a clinical eye on your specific situation, starting a free consultation with one of our GPhC-registered prescribers is the most direct next step. A real clinician reviews every request the same day.